Glioblastomas (GBM) are highly infiltrated by myeloidderived innate immune cells that contribute to the immunosuppressive nature of the brain tumor microenvironment (TME). CD47 has been shown to mediate immune evasion, as the CD47-SIRPa axis prevents phagocytosis of tumor cells by macrophages and other myeloid cells. In this study, we established CD47 homozygous deletion (CD47 Furthermore, TNC stimulated release of proinflammatory factors including TNFa via a Toll-like receptor 4 and STAT3-dependent mechanism in human macrophage cells. These results reveal a vital role for TNC in immunomodulation in brain tumor biology and demonstrate the prominence of the TME extracellular matrix in affecting the antitumor function of brain innate immune cells.
Introduction
Gliomas account for 70% of all adult brain tumors. Grade IV astrocytoma, glioblastoma (GBM), is the most common and aggressive primary brain tumor, accounting for approximately 50% of all glial tumor types. Because of tumor heterogeneity and the blood-brain barrier, GBM remains refractory to current treatment modalities including surgery, radiotherapy, and chemotherapy; the median survival time of patients with GBM is approximately 15 to 20 months (1) . Recent progress in immunotherapy-based treatment options in other tumor types has encouraged interest in developing similar approaches that might be effective for this devastating malignancy (2) . However, current immunotherapies have not yet improved the survival of GBM patients (3) . Understanding how tumor interacts with brain immune systems, including the innate immune system, and developing improved therapeutic options for GBM are urgently needed.
Innate immune cells, such as microglia, macrophages, and myeloid-derived suppressor cells, are known to be present within GBM. Tumor-associated microglia/macrophages (TAM) contribute to 30% to 50% of brain tumor mass (4, 5) and are educated by tumor cells to acquire a tumor-promoting M2-like phenotype that is able to produce anti-inflammatory and immune-suppressive factors in the tumor microenvironment (TME). In GBMs, TAMs with different phenotypes coexist, including an antitumor, proinflammatory M1-like phenotype. The activation status rather than the abundance of TAMs present in the TME has been shown to have prognostic value (6) . TME can influence the properties of TAMs (7) . Extracellular matrix (ECM) is an important component of the TME and is composed of a complex mixture of macromolecules including glycoproteins, proteoglycans, and polysaccharides. A body of evidence indicates that in addition to their canonical role in maintaining and regulating tissue organization, ECM components function as signaling molecules by interacting with membrane-bound receptors to regulate cell growth, motility, and immune response (8) . Although tightly controlled during embryonic development and organ homeostasis, these ECM-mediated pathways are commonly deregulated and disorganized in cancer. How ECM regulates immune response of brain tumors is largely unknown.
In this study, we used CD47 knockout (KO) human and mouse glioma models to investigate how ECM modulates the interactions between brain tumor cells and the innate immune system. CD47, also known as integrin-associated protein, is a ubiquitous 50 kDa membrane-bound protein consisting of a single N-terminal IgV extracellular domain, five membrane-spanning segments, and a short C-terminal cytoplasmic tail (9) . CD47 has been reported to mediate immune evasion by interacting with the signal regulatory protein-alpha (SIRPa) expressed on macrophages and other myeloid cells (10) . CD47 binding to SIRPa causes phosphorylation of the SIRPa cytoplasmic immunoreceptor tyrosine-based inhibition motifs, leading to the recruitment of Src homology 2 domain-containing tyrosine phosphatases, which prevents myosin-IIA accumulation at the phagocytic synapse and consequently inhibits phagocytosis (11) . Thus, the CD47-SIRPa axis, also known as a "don't eat me" signal, functions as a negative checkpoint for innate immunity. CD47 expression is elevated in many cancers; The Cancer Genome Atlas data analysis indicated that high CD47 expression in GBM correlates with poor patient survival (12) . Blocking the CD47/SIRPa interaction facilitates phagocytosis and inhibits tumor growth in many preclinical cancer models (12, 13) ; for example, the administration of anti-CD47 mAbs reduced tumor growth and prevented lung cancer progression (14) .
Abundant evidence supports that the signaling functions of CD47 go well beyond this passive antiphagocytic role, with CD47 acting as a sensor for cell-microenvironment signals. As an example, CD47 interacts with other signaling molecules including the matricellular glycoprotein thrombospondin-1 (TSP-1; refs. 15, 16) to regulate various cellular functions including cell migration, axon extension, cytokine production, and T-cell activation (17) (18) (19) . Therefore, it is critical to dissect the signaling network of CD47 in tumor cells and tumor cell-immune cell interactions. The current study in GBM models is aimed to understand how TME influences host response to tumor cells carrying CD47 KO. We found that CD47 KO dramatically increased tumor-associated ECM protein tenascin C (TNC) in vitro and in vivo. Our results demonstrate the importance of the ECM protein in the antitumor function of brain innate immune cells.
Materials and Methods

Reagents and cell cultures
All reagents were purchased from MilliporeSigma unless otherwise stated. Human GBM cells U87, mouse glioma cells GL-261, and human monocyte cells THP-1 were original purchased from the ATCC. All cell lines are free from Mycoplasma and authenticated with short tandem repeat profiling by Johns Hopkins Genetic Resources Core facility using Promega GenePrint 10 system.
Generation of CD47 KO cell lines by CRISPR-Cas9 system
Cas9-GFP plasmid was purchased from Addgene. For targeting CD47, two gRNAs targeting CD47 were cloned into pX330M (Addgene) according to the addgene cloning protocol. Human CD47 gRNA targeting sequences were: 5 0 -CGACCGCCGCCG CGCGTCACAGG (intron) and 5 0 -CAGCAACAGCGCCGCTAC-CAGGG (first exon). Mouse CD47 gRNA targeting sequences were: 5 0 -cccttgcatcgtccgtaatgtgg (intron) and 5 0 -cagtagttttctttacgttaagg (first exon). Glioma cells (2 Â 10 5 per well in 6-well plate) were cotransfected with the two gRNA plasmids and Cas9-GFP using lipofectamine 3000. After 2 days, transfected cells were sorted by flow cytometry (GFP þ ) and subcloned. Genomic DNA was extracted from clonal cells and amplified using the primer set as follows: for human: forward: 5 0 -GTCTGGAGCCTGCGACTG; reverse: 5 0 -GTGTGTGCATTTGGAGATGG; for mouse: forward: 5 0 -gtctactggctggtgtgcaa; reverse: 5 0 -catcgcgcttatccattttc. Sanger sequencing of the PCR products was performed to screen CD47 genomic KO.
Preparation of cell lines with TNC knockdown using shRNA and lentivirus system
To knock down TNC expression, lentivirus containing a control nonsilencing (NS) sequence or TNC shRNA in a GIPZ viral vector (Thermo Fisher Scientific) containing the GFP coding frame was introduced into cells (20) .
Cell migration assay
Migration was quantified by Boyden chamber transwell assays (8-mm pore size; Corning Costar) following our published work (21, 22) .
Quantitative real-time PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen). After reverse transcription using cDNA reverse transcriptase (Applied Biosystems) and Oligo(dT) primer, quantitative realtime PCR (qRT-PCR) was performed using SYBR Green PCR Mix (Applied Biosystems) and IQ5 detection system (Bio-Rad). Primer sequences used in this study were listed in Supplementary Table  S1 . Relative gene expression was normalized to GAPDH.
Immunoblot
Proteins were detected and quantified using the Odyssey Infrared Imager (LI-COR Biosciences) with secondary antibodies labeled by IRDye infrared dyes (LI-COR Biosciences) and normalized to GAPDH or b-actin following our published work (20) . The antibodies used for this study were listed below, most of them from Cell Signaling Technology unless otherwise stated: CD47 (Santa Cruz Biotechnology); TNC (mouse and human, MilliporeSigma); TNC (human only, Santa Cruz Biotechnology); STAT-3; phospho-STAT-3; Akt; phosphor-Akt; Jagged-1; NOTCH1; NICD; b-actin (MilliporeSigma); GAPDH (MilliporeSigma).
ELISA of TNFa
Human monocyte cells THP-1 were seeded onto 12-well plates (1.5 Â 10 5 /well) and incubated with phorbol 12-myristate 13-acetate (PMA, 25 ng/mL) for 48 hours to introduce differentiation. Cells were treated with TNC protein at 1, 3, and 10 mg/mL for another 8 hours in serum-free medium, and the supernatant was collected for TNFa measurement using a TNFa ELISA kit (R&D Systems). TNC was purchased from Millipore and purified from the conditioned medium of human U251 GBM cell line by chromatography. All measurements were conducted according to the manufacturer's protocol using a microplate spectrophotometer (Molecular Devices). For some experiments, cells were incubated with STAT3 inhibitor (Stattic, 5 mmol/L) or TLR-4 inhibitor (TAK242, 10 mmol/L) for 1 hour prior to TNC treatment.
In vitro phagocytosis assay THP-1 cells were seeded onto 12-well plates (1.5 Â 10 5 /well) and incubated with PMA (25 ng/mL) for 48 hours to induce differentiation. Cancer cells were labeled with carboxyfluorescein succinimidyl ester (CFSE; Thermo Fisher Scientific) following the manufacturer's protocol. For each experiment, CFSE-labeled tumor cells (3 Â 10 5 ) were added to macrophages and incubated in a final volume of 1 mL serum-free medium at 37 C for 2 hours. Macrophages were stained with CD11c-APC (Thermo Fisher Scientific) for 30 minutes. Phagocytosis was assessed by flow cytometry (BD). Nonstained and CD11c-APC-stained THP-1 cells were used for proper gating of flow cytometry analysis.
Tumor xenografts and immunofluorescent images
For intracranial xenografts, 8-week-old female SCID (NCI) received 100,000 viable CD47 WT or CD47
À/À U87 cells in 2 mL of PBS by stereotactic injection into the right caudate/putamen. Mice were sacrificed approximately 3 to 4 weeks after implantation, and tumor volumes were estimated based on the formula:
vol ¼ (sq. root of maximum cross-sectional area) 3 (23) . All animal protocols used in this study were approved by the Johns Hopkins School of Medicine Animal Care and Use Committee.
Immunofluorescent staining of tumor sections was performed following the protocol in Wu and colleagues (24) . The primary antibodies used for immunofluorescent staining were as following: Iba-1 (Wako, ThermoFisher); iNOS (ThermoFisher); TGM2 (Cell Signaling Technology); Arginase-1 (Cell Signaling Technology). Immunofluorescent images were taken under fluorescent microscopy and analyzed using Axiovision software (Zeiss). Fluorescent microphotographs were taken, and positive stainings were manually counted or quantified by ImageJ (NIH).
Statistical analysis
Statistical analysis was performed using Prism software (GraphPad). Post hoc tests included the Student t test and Tukey multiple comparison tests as appropriate. Data are represented as mean value AE SEM, and significance was set at P < 0.05.
Results
CD47 KO increases glioma cell phagocytosis
We employed the CRISPR-Cas9 technique to completely knockout CD47 expression in human GBM cells to investigate the effect of CD47 loss of function on phagocytosis and tumor growth. Two guide RNAs (gRNA) separated by 108 bp and designed to target the first exon of CD47 were transfected into U87 GBM cells (Fig. 1A) . In all, approximately 20 clones were selected and analyzed via PCR for CD47 KO using a primer pair flanking the two gRNA target sites. Clones with heterozygous CD47 deletion produced two PCR products of 588 bp and 480 bp, and homozygous deletion generated one 480 bp PCR product (Fig. 1B) . Sanger sequencing confirmed the homozygous deletion of the 108 bp targeted CD47 genomic sequence in cells from clone 7 and clone 21 (CD47 À/À , Fig. 1C ). Cell surface CD47 expression was absent in these two CD47 À/À clonal lines as measured by both flow cytometry (Fig. 1D ) and immunofluorescence (Fig. 1E) .
Cell monolayer proliferation assays showed no significant difference in cell growth between CD47
À/À cells and CD47
wild-type (WT) control cells (Fig. 1F ). Transwell migration assays revealed that CD47 KO did not have a consistent effect on tumor cell migration, with clone 7 CD47 KO cells migrating slower than CD47 WT cells, but clone 21 similar to that of control (Fig. 1G ).
Human monocyte cells THP-1 were differentiated into macrophages by PMA (25 ng/mL, 48-72 hours) and used to evaluate the effect of CD47 KO on phagocytosis of U87 cell. CD47 WT and CD47
À/À cells were labeled with CFSE, which covalently reacts with amine-containing residues of intracellular proteins. Labeled U87 cells were cocultured with differentiated THP-1 cells for 2 hours. The mixture was harvested and stained with the macrophage-specific antibody CD11c conjugated with allophycocyanin (APC (Fig. 1I , n ¼ 6, P < 0.001). This result is consistent with an antiphagocytosis function of CD47 expression on tumor cells.
CD47 loss of function decreases GBM xenograft growth
We examined how CD47 KO affected GBM xenograft growth. U87 WT or CD47 À/À cells (100,000) were separately injected into the caudate/putamen of Balb/c immunodeficient (SCID) mice (experiments were repeated once, n ¼ 8 total); animals were sacrificed approximately 4 weeks after implantation, and brain sections were stained with hematoxylin and eosin (H&E; Fig. 2A Fig. S1A and S1B).
These findings, in conjunction with our results showing that CD47 KO minimally affected the growth rate and migration of U87 cells while increasing macrophage phagocytosis of tumor cell in vitro, led us to hypothesize that the substantial differences in WT and CD47 À/À in vivo growth patterns resulted from differences in interactions between tumor cells and innate immune cells.
CD47 loss of function recruits more TAMs
The glioma-associated innate immune system, the main constituents of which are TAMs, remains intact in SCID mice. We examined TAMs in CD47 WT and CD47 À/À xenografts using specific markers. Immunofluorescence staining of the general microglial/macrophage marker Iba-1 revealed that consistent with reports from others (25), TAMs formed a dense band surrounding the WT tumors and appeared sparsely within the tumors (Supplementary Fig. S2 ). The morphology of TAMs in the tumor core resembled amoeboid-like microglia/macrophages with stout processes (Fig. 3A, top plots) . In CD47 À/À xenografts, the morphology of TAMs in the tumor core was similar to that of controls, but we observed an increase in the density of TAMs in CD47 KO xenografts (Fig. 3A, bottom plots) . The average number of Iba-1 þ cells per microscopic field was 105 in CD47 À/À xenografts, almost 2-fold higher than that of control ( Fig. 3B , P < 0.05). CD47 antibody has been shown to drive M2 to M1 polarization of macrophages in vitro (26) . We asked if CD47 KO induces an increase in M1-like TAMs in GBM orthotopic xenografts. Expression of M1 marker iNOS (27) S3A). On the other hand, the xenografts were infiltrated with M2-like TAMs as evidenced by Arg-1, which costained with Iba-1 (Fig. 3C) . The average number of Arg-1 þ TAMs per microscopic field was significantly increased by CD47 KO, from 22 in WT tumors to 48 in CD47 À/À tumors ( Fig. 3D , P < 0.05). Another M2 marker TGM2 also increased by approximately 3-fold in CD47
À/À xenografts ( Supplementary Fig. S3B ).
To determine if CD47 KO stimulated phagocytosis in vivo, we costained brain sections with Iba-1 (Fig. 3E, green) and human nuclear-specific antigen (Fig. 3E, HuNu, red) . Confocal microscopic analysis demonstrated the engulfment of tumor cells by microglia/macrophages (Fig. 3F, arrows) . We counted total Iba-1 These data suggested that CD47 KO inhibited tumor growth by promoting phagocytosis through the recruitment of M2-like TAMs.
CD47 KO upregulates TNC TNC is a major ECM molecule in glioma and influences parenchymal-tumor cell interactions (30) . Immunofluorescence staining with an antibody recognizing both mouse and human TNC revealed a dramatic increase in TNC expression in CD47 À/À xenografts (Fig. 4A) . To determine the source of the increased TNC, we stained tumor sections with a species-specific antihuman TNC antibody and found a significant increase in the expression of human TNC in CD47 À/À xenografts as well ( Fig. 4B and C, P < 0.001). RT-PCR and Western blot analysis of TNC expression in vitro confirmed that CD47 KO upregulated TNC expression by approximately 2-fold at the mRNA level, and approximately 4-to 5-fold at the protein level ( Fig. 4D and E, P < 0.05). Cell signaling pathways were examined to determine the molecular mechanism by which CD47 KO increased TNC expression in GBM cells. Western blot analysis was employed to screen alterations in AKT, MAPK, Notch, and Wnt pathways. Several Notch pathway effectors, including Jagged-1, NOTCH1, and (Fig. 4F) . Jagged-1 and NOTCH1 mRNA levels were also upregulated in CD47 À/À cells (Fig. 4G )
. Treating cells with the specific Notch pathway inhibitor DAPT (N-[N-(3,5-Diflurophenaacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester) decreased TNC protein level in CD47
À/À cells but not in WT cells (Fig. 4H) , suggesting that Notch signaling was a driver of TNC upregulation in the CD47 À/À cells.
TNC is also upregulated in mouse glioma cells with CD47 KO
To determine whether our major finding in SCID mice also applies to immunocompetent animal models, we knocked out Cd47 in mouse glioma GL261 cells using genome editing and gRNAs targeting mouse Cd47 exon 2 ( Supplementary Fig. S4A ). After subcloning and genotyping, we obtained GL261 cells with CD47 KO. Shown in Supplementary Fig. S4B is the Sanger sequencing of the PCR product from genomic DNA of GL261 clone 29 with a deletion of 161 bp at the Cd47 exon 2. Cell surface CD47 expression was absent in clone 29 as measured by flow cytometry (Fig. 5A ). CD47 KO did not alter GL261 proliferation and migration. Phagocytosis analysis with THP-1 cells confirmed that CD47 KO increased the phagocytosis index by approximately 2-fold from 19% to 40.1% in mouse glioma cells (Fig. 5B , P < 0.001). In immunocompetent syngeneic C57BL/6 mice, CD47 KO decreased xenografts growth from 97 to 18 mm 3 ( Fig. 5C and D, n ¼ 5, P < 0.05). Similarly, control GL-261 tumors displayed well-demarcated tumor margins, whereas Cd47 À/À tumors had irregular margins (Fig. 5E) . Furthermore, immunostaining of TNC in GL261 intracranial tumors indicated TNC was upregulated in Cd47 À/À tumors by nearly 3-fold ( Fig. 5F and G, P < 0.05), which was confirmed by Western blot analysis (3.5-fold) of GL261 cells in vitro (Fig. 5H ). This confirms that our findings in human GBM cells and SCID mice can be replicated in other model systems.
TNC knockdown abrogates the antitumor effect of CD47 KO We hypothesized that TNC upregulation contributed to tumor growth inhibition in CD47 À/À tumors. To test this, TNC expression in U87 control and CD47 À/À cells was knocked down using TNC shRNA because TNC was more prominently upregulated by CD47 loss of functions in U87 cells. TNC shRNA decreased TNC expression by approximately 80% in both CD47 WT and CD47 À/À cells relative to control cells transduced with NS shRNA (Fig. 6A) , consistent with the efficiency previously described by us (20) . TNC knockdown (KD) did not affect cell growth rate in vitro (Fig. 6B) . Orthotopic tumor xenografts from U87 CD47 WT and CD47
À/À cells with or without TNCKD were used to investigate the role of TNC upregulation in the altered growth of CD47 À/À xenografts.
Animals were sacrificed around postimplantation day 18. H&E staining of brain sections revealed that TNCKD increased the size of CD47 À/À xenografts from 11 to 30 mm 3 ( Fig. 6C and D, P < 0.05). Knocking down TNC alone in CD47 WT tumor cells also increased tumor growth from 27 to 101 mm 3 (P < 0.05), consistent with our previous published work that TNC loss of function increased tumor growth (28) . The size of CD47 À/À þ TNC KD xenografts was significantly smaller than that of CD47 WT þ TNC KD, indicating CD47 KO dramatically impairs tumor growth even when TNC was knocked down (P < 0.05). Immunofluorescence staining confirmed TNC downregulation in xenografts derived from TNC shRNA transduced cells (Fig. 6E) . Anti-Iba-1 and anti-Arg-1 immunofluorescence was used to investigate how changes in microenvironmental TNC levels altered interactions between TAMs and tumor cells. TNCKD abrogated the increase in TAM recruitment induced by CD47 KO (Fig. 6F) Fig. S5 ).
TNC modulates tumor cell-immune cell interactions
Our in vivo results support a mechanism by which microenvironmental TNC mediates antitumor responses to CD47 KO. As an extracellular protein involved in integrin binding and (31, 32) , we hypothesized that this function of TNC reflected changes in tumor cell phagocytosis by TAMs. Indeed, we found TNCKD inhibited phagocytosis triggered by CD47 KO in vitro (Fig. 7A) . As shown before, CD47 KO increased phagocytosis of control U87 cells by approximately 3-to 4-fold, from 15.2% to 49.1%. TNCKD significantly decreased phagocytosis induced by CD47 KO from 49.1% to 28% (Fig. 7B, P < 0.05) . We also noticed that compared with U87 CD47 WT cells, TNCKD decreased the baseline phagocytosis from 15.2% to 8.1%, which may partially explain the increased tumor size from CD47 WT þTNCKD cells. Our findings suggest that elevated expression of TNC in CD47 À/À cells promoted phagocytosis, and TNC expression in tumor cells could contribute to baseline phagocytosis independent of CD47. Because TNC is upregulated in response to inflammation (33), we hypothesized that TNC may elicit other immunomodulation functions to facilitate tumor cell-immune cell interactions. To this end, we studied TNC gain of function using exogenous TNC. THP-1 cells were treated with human TNC (1-10 mg/mL) for 8 hours followed by RT-PCR to measure the expression level of several proinflammatory factors including IL1b, IL6, and TNFa. Cells treated with lipopolysaccharides (LPS) were used as a positive control. Real-time quantitative RT-PCR revealed a concentration-dependent upregulation of these proinflammatory Fig. 7C , P < 0.05). ELISA of THP-1 conditioned medium revealed concentration-dependent increase in TNFa production driven by TNC (Fig. 7D, P (Fig. 7E and F, P < 0.05). This result indicated that TNC upregulation driven by CD47 KO is involved in the increased cytokine production.
STAT3 was activated in THP-1 cells following TNC treatment (Fig. 7G) . The STAT3-specific inhibitor stattic (5 mmol/L) prevented STAT3 activation in TNC-treated THP-1 cells and inhibited TNFa production induced by TNC (Fig. 7H, P < 0.05) . Preincubating THP-1 cells with the Toll-like receptor 4 (TLR4) inhibitor TAK242 (10 mmol/L) also inhibited TNC-induced STAT3 activation and TNFa production ( Fig. 7I and J, P < 0.05). Taken together, our results indicated that the ECM protein TNC activated STAT3 and induced the secretion of proinflammatory factors in macrophage cells, which may explain the systemically increased recruitment of TAMs in CD47 À/À xenografts.
Discussion
In this work, we established CD47 loss of function in GBM cells to investigate the impact of eliminating the "don't eat me" signal on tumor growth and tumor-TME interactions. CD47 KO significantly decreased intracranial tumor growth by recruiting more M2-like TAMs and inducing phagocytosis. We found that CD47 KO in glioma cells upregulated the ECM protein TNC in vitro and in both SCID mice and immunocompetent mice. Knocking down TNC expression in tumor cells reversed CD47 KO-mediated phagocytosis in vitro and its antitumor effect in vivo. We also found TNC may elicit a systematic immunomodulation role via binding to TLR4 in macrophages to activate STAT3 and stimulate release of proinflammatory factors including TNFa. To the best of our knowledge, this is the first study to link TNC to CD47-mediated phagocytosis signaling and demonstrate the importance of TNC in affecting the antitumor function of brain TAMs.
Our in vitro and in vivo phagocytosis analyses of CD47 KO cells are consistent with previous studies by others demonstrating that targeting the CD47-SIRPa axis with specific blocking antibody increases phagocytosis (12) (13) (14) . CD47 is a multifaceted molecule that interacts with many receptors/ligands to mediate a variety of biological functions. Our data suggest that apart from the "don't eat me" signaling pathway, CD47 KO also affects other pathways and molecules. It has been reported that CD47 serves as the receptor for matricellular protein TSP-1, a prototype of the matricellular protein family with members like TNC and secreted protein acidic and rich in cysteine (SPARC). TSP-1 is implicated in angiogenesis, which may explain changes in laminin staining observed in CD47 À/À xenografts. Our data also found that TNC was upregulated by CD47 KO via a Notch-mediated mechanism, consistent with report from Sivasankaran and colleagues that the activation of the Notch pathway increased TNC expression (34). Kaur and colleagues reported that CD47 knockdown leads to c-Myc activation and stem cell marker expression such as KLF4, OCT 4, and Sox2 (16) . In GBM, the Notch pathway has been implicated in GBM stem cell biology (35) . Therefore, it is tempting to speculate that CD47 KO upregulates the Notch pathway via alteration in stem cell-related pathways. On the other hand, studies from Sarkar and colleagues indicated Notch activation is downstream of TNC signaling in brain tumor stem cells (36) . A detailed link between CD47 KO and TNC is currently under investigation.
In immunodeficient mice (SCID), the adaptive immune system, including T cells and B cells, is deficient; whereas the innate immune system, including microglia, macrophage, and natural killer cells, remains intact (37) . The size of CD47 À/À xenografts was much smaller compared with that of control, yet the number of infiltrating TAMs in CD47 À/À xenografts was significantly higher than that of control. We reasoned that phagocytosis/ cytotoxicity mediated by TAMs was the main contributor of the decreased tumor size in CD47 À/À xenografts, because our in vitro analysis showed no growth difference between CD47 WT cells and CD47 À/À cells. Our in vivo Ki67 staining further confirmed this.
Thus, depending on the TME, high TAM density was not always associated with more aggressive tumors. Works from Loane and colleagues (38) indicated that TAMs with amoeboid-like shape were motile, whereas the hypertrophic morphology of TAMs was associated with a phagocytic activity. In our models, the morphology of TAMs in CD47 À/À xenografts was similar to that of controls with amoeboid-like shape. The increased density of Arg-1 þ in CD47 À/À xenografts suggested that more M2-like TAMs were recruited by CD47 KO xenografts. Although Zhang and colleagues reported that anti-CD47 antibody repolarized M2 macrophage to M1 macrophage (26), we did not observe such repolarization of TAMs following CD47 KO in our models. However, we were able to demonstrate the increased phagocytosis ability of TAMs in CD47 À/À xenografts by double staining of human nuclei and Iba-1 in TAMs, consistent with studies for Leidi and colleagues demonstrating that M2-like TAMs also have phagocytic ability (39) . Compared with U87 WT xenografts that always form ball-like solid tumors, the histopathologic features of CD47 KO xenografts show invasive margin of xenografts. This could be either from the increased phagocytosis by infiltrating microglia/macrophages or increased tumor cell migration due to high TNC level. Because the effect of CD47 KO on tumor cell migration was not consistent in different clones, we reason that the increased phagocytosis may be the main cause for the dramatic change in the histopathologic features of CD47 KO xenografts.
One of the interesting findings in this study is to link TNC as a modulator of phagocytosis in brain cancer. Our findings are in line with works regarding TNC function in the periphery system (40, 41) . TNC is one of the most abundant ECM proteins in the brain TME, and its expression correlates with GBM progression. Our findings that TNC was upregulated following CD47 KO and plays a beneficial role to facilitate phagocytosis are counterintuitive but not surprising as we have previously reported that targeting TNC in GBM stem-like neurosphere cells inhibited tumor migration but promoted tumor growth in vivo (20) . As a consequence of its complex structure, TNC functions as an ECM molecule to activate the integrin signaling pathway during adhesion, migration, and cytoskeleton rearrangement, which may also contribute to increased phagocytosis in CD47 À/À xenografts as the phagocytosis process employs cytoskeleton such as myosin to form phagocytosis cup. Besides this, we also found that TNC may elicit a systematic role to facilitate phagocytosis by inducing proinflammatory factors, which may recruit more immune cells to attack tumor cells. It has been well-documented that TNC is upregulated during inflammation and plays an important role in wound healing (42, 43) . In arthritic joint diseases, TNC has been reported to function as an endogenous activator of TLR4 via its fibrinogen-like domain to induce inflammation (43) . Our results of TNC function in brain tumor are consistent with the function of TNC in the periphery system. With the findings that TNC is dramatically upregulated in CD47 À/À xenografts and modulates phagocytosis, it is appealing to think that instead of being a promoter of tumor malignancy, the elevated TNC in brain tumors may be a defensive mechanism by the innate system to try to eliminate malignant cells. Over the past years, the use of immune-checkpoint inhibitors to target the adaptive immune systems has been one of the most significant advances in antitumor treatment. However, the increased use of these agents has led to an augmented appreciation that they were not suitable for all patients. Recent studies have indicated that the innate immune system checkpoint such as CD47 may be an interesting therapeutic target (44) . A better mechanistic understanding of CD47 signaling network will aid in the development of novel antitumor reagent. Our study provides the first evidence demonstrating that microenvironmental TNC is involved in phagocytosis of tumor cell by TAMs. Future studies of the precise mechanism by which TNC regulates phagocytosis will shed light on how to exploit the innate immune system to target brain tumors.
